A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the results suggest a breakthrough in active amyloid clearance.